Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Other Non-Current Assets: 2013-2025

Historic Other Non-Current Assets for Ocular Therapeutix (OCUL) over the last 12 years, with Sep 2025 value amounting to $1.6 million.

  • Ocular Therapeutix's Other Non-Current Assets changed negligibly% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $1.6 million for FY2024, which is negligibly% changed negligibly from last year.
  • Ocular Therapeutix's Other Non-Current Assets amounted to $1.6 million in Q3 2025, which was down 0.00% from $1.6 million recorded in Q2 2025.
  • Over the past 5 years, Ocular Therapeutix's Other Non-Current Assets peaked at $1.8 million during Q1 2021, and registered a low of $1.6 million during Q4 2023.
  • Its 3-year average for Other Non-Current Assets is $1.7 million, with a median of $1.6 million in 2025.
  • Data for Ocular Therapeutix's Other Non-Current Assets shows a maximum YoY decreased of 8.50% (in 2023) over the last 5 years.
  • Ocular Therapeutix's Other Non-Current Assets (Quarterly) stood at $1.8 million in 2021, then remained steady at $1.8 million in 2022, then decreased by 8.50% to $1.6 million in 2023, then remained steady at $1.6 million in 2024, then remained steady at $1.6 million in 2025.
  • Its last three reported values are $1.6 million in Q3 2025, $1.6 million for Q2 2025, and $1.6 million during Q1 2025.